Abstract Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) regulates the basal and stress-
inducible expression of a battery of genes encoding key components of the glutathione …

Human aldo-keto reductases (AKRs) catalyze the NADPH-dependent reduction of carbonyl
groups to alcohols for conjugation reactions to proceed. They are implicated in resistance to …

Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a
given patient population. It is a negative prognostic and predictive factor owing to its multiple …

Tumour hypoxia has been pursued as a cancer drug target for over 30 years, most notably
using bioreductive (hypoxia-activated) prodrugs that target antineoplastic agents to low …

Hypoxia-activated prodrugs (HAPs) are designed to specifically target the hypoxic cells of
tumors, which are an important cause of treatment resistance to conventional therapies …

This review examines the vast catalytic and therapeutic potential offered by type I (ie oxygen-
insensitive) nitroreductase enzymes in partnership with nitroaromatic prodrugs, with …

PR-104, currently in phase II clinical trials, is a phosphate ester pre-prodrug which is
converted in vivo to its cognate alcohol, PR-104A, a prodrug designed to exploit tumor …

Human aldo-keto reductase family 1 member C3 (AKR1C3) is known as a hormone activity
regulator and prostaglandin F (PGF) synthase that regulates the occupancy of hormone …

Recent studies indicate that interactions between leukemia cells and the bone marrow (BM)
microenvironment promote leukemia cell survival and confer resistance to anti-leukemic …

Aldo-keto reductase (AKR) 1C3 (type 5 17β-hydroxysteroid dehydrogenase and
prostaglandin F synthase), may stimulate proliferation via steroid hormone and …